This is a signal that PDSB's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options. A.I.dvisor looked back and found 31 similar cases where PDSB's RSI Indicator left the overbought zone, and in of them led to a successful outcome. Odds of Success:
a developer of clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers